Keybanc analyst John Vinh maintains Monolithic Power Systems (NASDAQ:MPWR) with a Overweight and lowers the price target from $580 to $500.
Israel-Based Clearmind Medicine Shows Efficacy Of Psychedelic Derived Obesity Treatment In Pre-Clinical Trial
In a series of pre-clinical trials, Clearmind's drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin sensitivity
Tel Aviv, Israel / Vancouver, Canada, Jan.